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Despite effective surgical methods for non-melanoma skin cancer (NMSC), patients suffer
from tissue damage, scarring, or even disfigurement; thus, there is a need for
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chemopreventive approaches. Because of the complex interplay between glucocorticoids
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(GCs), inflammation, and cancer, we sought to determine the role of 11β-hydroxysteroid
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dehydrogenase 1 and 2 (11βHSD1 and 2) in regulating GCs during skin cancer
development and progression. 11βHSDs modulate the activation of GCs in a tissue-
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specific manner and have been reported to play a role in development and progression of
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reduction in colony formation in vitro. Finally, our in vivo study elucidated that inhibition of

other types of cancer, but their role has not yet been reported in NMSC. Here, we found a
significant upregulation of 11βHSD2 protein in skin cancer cells when compared to normal
skin cells, suggesting a role for this enzyme in the multifactorial process of skin cancer
development. In addition, inhibition of 11βHSD2 with siRNA resulted in significant
11βHSD2 with pharmacological inhibitor, Glycyrrhetinic acid (GA) could significantly
diminish tumorigenesis in a well-studied in vivo mouse model of NMSC. Overall, these
studies highlight for the first time a potential novel role for 11βHSD2 in NMSC
development and may allow for new GC treatment approaches capable of avoiding
deactivation by the enzyme. If 11βHSD2 can be inhibited as we have done here, or
circumvented using modified GCs, this may lead to more efficacious outcomes for NMSC
patients by preventing deactivation of the GC and minimizing resistance.
KEYWORDS

11β-hydroxysteroid dehydrogenases, chemoprevention, glucocorticoids, glycyrrhetinic acid,
non-melanoma skin cancer, phytochemicals

1 | INTRODUCTION

incidence that is continuing to rise annually.1–4 Between 2002-2006
and 2007-2011, the average annual total cost for skin cancer increased

Non-melanoma skin cancer (NMSC) poses a significant public health

by 126.2%, as compared to the average annual total cost for all other

problem as it is the most prevalent malignancy in the United States

cancers increased only by 25.1%.5 The increasing incidence of both

with an estimated 2-3 million new diagnoses each year and an

NMSC diagnoses and rapidly expanding treatment costs demonstrate

Abbreviations: 11βHSD1, 11-beta hydroxysteroid dehydrogenase 1; 11βHSD2, 11-beta hydroxysteroid dehydrogenase 2; DMBA, 7,12-dimethylbenz[a]anthracene; GA, Glycyrrhetinic acid;
GC, Glucocorticoid; GR, Glucocorticoid receptor; MTT reagent, thiazolyl blue tetrazolium bromide; TPA, 12-O-Tetradecanoylphorbol-13-acetate.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2018 The Authors. Molecular Carcinogenesis Published by Wiley Periodicals, Inc.
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the considerable need for prevention-based approaches towards

validated our 11βHSD2 characterization results from our in vitro

NMSC. Therefore, we have focused our studies on chemopreventive

mouse studies using a human in vitro model of NMSC to ascertain

strategies which target the inflammation gatekeepers, GCs, to

whether the same results could be achieved in a human model for

effectively diminish tumorigenesis.

clinical relevance. Finally, we performed an in vivo, two-stage mouse

The modulation of GCs at the pre-receptor level is both

carcinogenesis study over the course of 30 weeks to study the effect

necessary for their proper function and essential for tissue-specific

of 11βHSD2 inhibition by GA on DMBA/TPA-induced tumorigene-

glucocorticoid requirements. While GCs are regulated by ligand and

sis. Our in vitro results in both mouse and human NMSC cell models

receptor concentrations in the plasma, an additional and vital level of

show an upregulation of 11βHSD2 in cancer cells versus normal skin

pre-receptor modulation of these critical hormones is carried out by

cells. Moreover, upon addition of a tumor promoter to induce

6

11β-hydroxysteroid dehydrogenases (11βHSDS). The function of

transformation, we see an upregulation of 11βHSD2 in pre-

these enzymes is of vital importance for localized activation and

neoplastic mouse keratinocytes. Corresponding with these results,

deactivation of GCs.7 11βHSD1 and 11βHSD2 catalyze the

our in vivo mouse studies also suggest a critical role for this enzyme

interconversion of active GCs to their inactive counterparts such

in tumorigenesis as inhibition of 11βHSD2 with GA considerably

as the conversion of cortisol to cortisone by 11βHSD2 and, the

delayed tumor onset and significantly decreased tumor incidence.

reverse reaction whereby 11βHSD1 results in an active cortisol

Given the ability of GCs to alter signaling in key survival pathways

molecule.8 Specifically, 11βHSD2 deactivates GCs by converting the

and the fact that similar to many chemotherapeutic agents, skin

hydroxyl group on the C-11 position to a ketone group, rendering it

cancer patients often develop resistance to GC therapy, an

9,10

Through the

investigation into the role of 11βHSD2 in skin cancer develop-

enzymatic action of 11βHSD2, the amount of active GC which is

ment/progression and GC resistance is of significant relevance. As

inactive; it does this in a tissue specific manner.

available to the receptor can be carefully modulated within the

stated before, characterization of 11βHSD2 in NMSC has never

designated target tissue, thus creating an advantageous target for

been evaluated elsewhere, therefore these findings elucidate an
important role for this enzyme in NMSC and may identify 11βHSD2

modulating GCs to combat tumorigenesis.
Significant evidence in the literature has shown that 11βHSD2 is

as a potential target for prevention and or therapy of NMSC.

expressed in many different cancer tissues, however, it is not expressed
in the normal tissue counterparts.11–13 Specific examples of this
11βHSD1/11βHSD2 expression “switch” as it is described in the

1.1 | Reagents

literature include occurrences in breast cancer, colon cancer, prostate,

DMBA, TPA, and GA were obtained from Sigma-Aldrich (St. Louis,

endometrial, and ovarian cancer cell lines.12,14–17 Given the fact that

MO). Stock solutions of GA (up to 20 mM) and TPA (10 mg/mL) were

GCs play an important role in skin proliferation and inflammation, it was

prepared in ethanol for in vitro studies and then diluted down for

surprising to find that 11βHSD2 characterization in NMSC has not yet

experiments. For in vivo studies, DMBA and TPA were prepared

been carried out. Moreover, this critical GC modulating enzyme has also

according to previously established protocol by Abel et al.18 For

not yet been evaluated for its role in transformation in NMSC, and it has

Western blotting analyses, primary antibodies used were for GR (Santa

been hypothesized that preferential expression of 11βHSD2 may play a

Cruz Biotechnology, Dallas, TX), 11βHSD1 (Santa Cruz Biotechnology),

Therefore, we

11βHSD2 (Abcam, Cambridge, MA), and β-actin (Abcam). Secondary

propose that NMSC development and progression may be circum-

antibodies for mouse and rabbit were both from Biorad (Biorad,

venting regulation of cellular proliferation by increasing expression of

Hercules, CA). Silencer select siRNA for 3 different regions of mouse

11βHSD2 and thereby locally inactivating GCs. As the “switch” in

11βHSD2 were obtained; S67837, S67838, and S67839 (Ambion,

11βHSD1/11βHSD2 expression has been reported in various cancer

Foster City, CA).

13

role in transformation of certain types of cancer.

types, much of the research on these enzymes as they relate to cancer
has now turned towards elucidating and characterizing the mechanisms
by which this change in expression is controlled.13 There is no doubt that

1.2 | Cell culture

this enzyme has a vital physiological role as it is normally responsible for

To investigate the importance of 11βHSDs in transformation using in

inactivating intracellular GCs in typical mineralocorticoid target tissues;

vitro skin cancer models, we employed the use of two well-

however, recent findings in the literature coupled with the unique role

established cell models of skin cancer; the JB6 mouse epidermal cell

that GCs play in skin cancer development and progression suggest that

lines generously provided to us by the laboratory of Nancy Colburn,

this enzyme may also play a substantial role in the multifactorial process

and a second model consisting of 3PC, MT1/2, and Ca3/7 cells

of NMSC transformation.

which was generated in our own lab, the laboratory of Thomas J.

In this study, we sought to characterize 11βHSD2 in in vitro

Slaga. The JB6 model consists of clonal genetic variants that are

mouse models of NMSC and to investigate whether it plays a role in

promotion-sensitive (P+), promotion-resistant (P−) or transformed

transformation. We utilized 11βHSD2 siRNA and pharmacological

(Tx). The JB6 model is a widely used inducible model to study

11βHSD2 inhibitor, Glycyrrhetinic acid (GA) to knock down

transformation, promotion, and progression at the molecular level.

11βHSD2 and study the effect this would have on TPA-induced

This model system of cell lines originated from untreated primary

transformation of well-established mouse models of NMSC. We also

BALB/c mouse epidermal cell cultures that gave rise at a very low

104
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frequency to immortalized cell lines.19 Then immortalized JB6 cells

which they were lysed and collected for whole cell Western blot

underwent further change to stably acquire sensitivity to induction

analysis.

of anchorage independence and tumorigenicity by TPA and other
tumor promoters.20 Nonselective cloning soon after observation of
this change lead to the development of clonal lines that were either
sensitive (P+) or resistant (P−) to tumor-promoter-induced neoplastic

1.5 | Anchorage independence assay of RT101 cells
transiently transfected with si_HSD2

transformation.19–21 Additionally, human epidermal cell lines repre-

Immediately following transient knockdown of 11βHSD2, a 104

senting different stages of malignant transformation, PM1 and Met4

aliquot of cells were taken and directly added to a 0.33% agar medium

were generously provided by the laboratory of C.M. Proby. JB6 P+

solution with 10%FBS. The cell suspension/agar medium solution was

and RT101 mouse epidermal keratinocytes were maintained in

poured as a top layer to previously prepared bottom layers of 0.5%

MEM containing 5% FBS, L-glutamine, sodium pyruvate, 50U/mL

agarose/10%FBS solution in a 6-well plate. Cells were culture at 37°C,

penicillin, and 50 ng/mL streptomycin. Cells were maintained in an

5% CO2 for 10-14 days. Where treatments were performed in soft

incubator at 5% CO2 and 37°C. 3PC, MT1/2, and Ca3/7 cells

agar, drug treatments were added to top layer prior to pouring, and

were maintained in Lonza (Houston, TX) liquid MEM Joklik (Cat no.

final concentration was adjusted accordingly; acetone was used as a

04-719Q) supplemented with transferrin (10 μg/mL), FBS (8%),

vehicle. After 10-14 days, colonies were stained using crystal violet

insulin

and quantified.

(5 μg/mL), EGF (5 ng/mL), o-phospoethanolamine (10 μM), 2-amino
ethanol (10 μM), gentamycin (50 μg/mL), and penicillin (50 U/mL)/
streptomycin

(50 ng/mL).

The

human

epidermal

cell

lines

1.6 | Animal model and experimental conditions

were maintained in minimum essential medium supplemented with

The ability of GA to inhibit tumorigenesis was examined by utilizing the

10% FBS, 2 mM L-glutamine, 50 U/mL penicillin, and 50 ng/mL

two-stage skin carcinogenesis model. Healthy female FVB mice aged

streptomycin.

6-7 weeks were obtained from Jackson Laboratories, Bar Harbor, ME.
Upon arrival, animals were randomly segregated into eight groups:
Control, DMBA/TPA, GA (low), GA (mid), GA (high), DMBA/TPA/

1.3 | Western blotting

GA(L), DMBA/TPA/GA(M), and DMBA/TPA/GA(H) (Figure 1). Each
5

JB6 P+ cells or RT101 cells were plated at 2.0 × 10 cells per 100 mm

group contained 28 animals total, with eight animals whose endpoint

culture dish. Cells were treated with 10 ng TPA or 0.1% vehicle

would be the short-term date, and 20 remaining animals whose

(acetone) for 24 h. Media was aspirated and cells were rinsed twice

endpoint would be at the end of the study (long term). Animals were

with cold PBS before lysis in buffer containing 1% Triton X-100, 0.5%

housed in a controlled atmosphere, under hygienic conditions, with

IGEPAL, 0.05 M TrisHCl, and 0.1 M NaCl as well as protease/

12-h light/dark cycles, and were provided standard animal feed. Prior

phosphatase inhibitors and 5 mM EDTA. Protein extraction was

to the start of the experiment, the animals were given an acclimation

performed by centrifugation and quantified by the BCA protein

period of 1 week. To expose the skin of the mice for topical treatments,

estimation method (Pierce, Waltham, MA). Proteins were separated

an approximate 2 × 3 cm portion of the dorsal region of each mouse

on 4-12% mini-protean gradient gels (Biorad), transferred onto

was shaved with surgical clippers 2 days prior to the start of any topical

nitrocellulose membrane, blocked in a 5% milk solution in PBST for

application of compounds.

1 h prior to overnight incubation with the designated primary antibody

Group 1 animals served as controls; these animals received topical

under refrigerated conditions. Membranes were next rinsed with

application of acetone only (200 μL/mouse). To induce skin tumori-

PBST, incubated in secondary antibody for a minimum of 1 h, and then

genesis, group 2 animals received a single topical application of DMBA

developed using Biorad Clarity™ Western ECL blotting substrate

(50 μg/200 uL of acetone) at the beginning of the study. One week

(Biorad). Imaging of developed Western blots was performed on an

later, group 2 received a topical application of TPA (2 μg/200 uL of

EPSON scanner, followed by densitometry measurements using

acetone) to the same site, which continued twice weekly for 27

IMAGEJ software.

consecutive weeks. Groups 3, 4, and 5 served as controls for
experimental groups, receiving only GA (twice weekly when experi-

1.4 | Transient knockdown of 11βHSD2 in JB6 P+
and RT101 cells

mental treatments were administered) at the following concentrations,
respectively; 0.25 μmol, 0.5 μmol, and 1 μmol. To examine the effect of
GA on development and progression of NMSC, animals in Groups 6, 7,

Transient knockdown of 11βHSD2 was performed using 11βHSD2

and 8 were treated with the same DMBA/TPA regimen as group 2,

siRNA (Ambion), non-targeted scrambled siRNA (Santa Cruz

however, they also received topical administration of GA at 30 min

Biotechnology), and a keratinocyte nucleofection kit (Lonza). JB6

prior to TPA in the same doses as in groups 3, 4, and 5. The number of

P+ and RT101 cells were transfected with 6 μL of non-specific

skin lesions >2 mm in diameter were counted and recorded each week,

scramble, 11βHSD2, or GFP siRNA duplexes by electroporation at

and general observations of the health and well-being of the animals

240 V/25 ms pulse length (Amaxa, MD). After transfection, cells

were recorded regularly. For further detail on treatments, a detailed

were plated into 100 mm dishes and allowed to grow for 48 h after

schematic is shown in Figure 1.
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FIGURE 1 Detailed animal treatment schedule to study the effect of Glycyrrhetinic acid on DMBA/TPA induced skin tumorigenesis. All
treatments described were administered topically in acetone to the shaved dorsal area of mice. Group 1, the control group mice were treated
with 200 μL acetone twice weekly throughout the treatment period, and at each instance where TPA was administered. In the DMBA/TPA
group, DMBA administration was performed only once at week zero to groups 2, 6, 7, and 8 in a dose of 50 μg/200 μL. In each group where
DMBA was administered, TPA was also given twice weekly at a dose of 2 μg/200 μL for the duration of the study. GA control, groups 3, 4,
and 5, each received their respective dose of GA (at 0.25 μmol, 0.5 μmol, and 1 μmol concentrations of GA) twice weekly. For our
experimental groups, 6, 7, and 8, GA was administered at the respective dose (0.25 μmol, 0.5 μmol, and 1 μmol) 30 min prior to TPA
treatment, twice weekly for entire length of the study

1.7 | Histopathologic examinations

1.9 | Statistical analyses

Normal, tumor-adjacent, and tumor samples were excised and

For in vitro studies, data are expressed as mean ± SD. Students t-test

collected at the end of both endpoints; therefore, samples were

or ANOVA were used to calculate P values, and statistical

collected after 15 and 27 weeks. Tissues were then fixed in 10%

significance was established at P < 0.05. All statistical analyses

formalin for later use. Later, the tissues were dehydrated in increasing

were performed using Graphpad Prism. For in vivo studies, data was

grades of alcohol, cleared in benzene, and embedded in paraffin wax.

collected for both tumor incidence and total number of lesions.

Sections then underwent hematoxylin and eosin staining (H&E) for

Tumor incidence was defined as the number of animals showing

microscopic evaluation of characteristic markers of TPA-induced

carcinogenic response/total number of animals in the group. For

epidermal hyperplasia, classification of papilloma, and identification of

comparisons between two groups, a Student's t-test was used, and

squamous cell carcinoma. H&E stained tissue sections were analyzed

when comparing multiple groups, ANOVA was used. For analyzing

by a pathologist who differentiated between normal mouse skin,

differences between groups over time, the fisher's exact test was

papilloma, and squamous cell carcinoma.

used to determine significance among two groups at a specific time
point. For all analyses, P < 0.05 was accepted for statistical

1.8 | Sample preparation

significance. All statistical analyses were performed using GraphPad
Prism (GraphPad, CA).

Normal, tumor-adjacent, and tumor samples were excised and
collected at the end of both endpoints; samples were collected after
15 and 27 weeks. Tissues were snap frozen in liquid nitrogen until a
later date upon which they were homogenized with a handheld
homogenizer and lysed via sonication on ice and in RIPA lysis buffer
(Pierce) containing protease and phosphatase inhibitor cocktail
(Thermo Fisher Scientific, MA). The homogenate was clarified by

2 | RESULTS
2.1 | 11βHSD2 expression is upregulated in mouse
and human in vitro models of NMSC when compared
to normal tissue counterparts

centrifugation at 12 000g for 15 min at 4°C. Protein lysates were

As upregulation of 11βHSD2 in tumors and cancer cells versus their

stored at −80°C until needed.

normal counterparts has been shown in several different cancer types,

106
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but has never been evaluated in NMSC, we characterized the protein

consisting of 3PC, MT1/2, and Ca3/7 cells. Our results showed that in

expression level of this enzyme in two well-established mouse skin

transformed RT101 cells, basal 11βHSD2 protein levels were

cancer models in order to determine whether 11βHSD2 was

significantly elevated when compared with levels in untreated, pre-

upregulated in skin cancer as it has been shown to be in other cancer

neoplastic JB6 P+ cells (Figure 2A). Further, 11βHSD2 protein

types in the literature. To investigate the expression of 11βHSD2 in

expression significantly increased in JB6 P+ cells after treatment

NMSC, we utilized the JB6 mouse epidermal keratinocyte model

with tumor promoter, TPA, when compared to acetone, the vehicle

consisting of P+ and RT101 cells, and a second mouse NMSC model

control (Figure 2A). When our second mouse NMSC model was

FIGURE 2 A, Representative Western blot and quantification showing increased 11βHSD2 expression in TPA-induced JB6 P+ cells as
compared to basal 11βHSD2 levels in vehicle treated JB6 P+ cells; Representative Western blot and quantification showing transformed
RT101 mouse epidermal keratinocyte cell lines have aberrant 11βHSD2 expression relative to normal or pre-neoplastic cell lines (JB6
P + without TPA treatment); Representative Western blot and quantification showing increased 11βHSD2 expression in papilloma-producing
MT1/2, and carcinoma-producing Ca3/7 cells as compared to non-tumorigenic 3PC cell lines. B, Representative Western blot and
quantification showing basal 11βHSD2 levels in PM1 dysplastic, pre-cancerous skin cells and Met4 skin cancer cells are significantly higher
than basal levels shown in normal HaCaT skin cells. C, Inhibition of 11βHSD2 via siRNA significantly decreases TPA-induced JB6 P+ and
RT101 colony formation in soft agar as determined by the anchorage independent colony formation assay. 11βHSD2 inhibition by siRNA pool
of 3 different siRNA results in significantly decreased colony formation in TPA-induced JB6 P+ cells and the same was observed in RT101
cells. These results were validated using the same 3 11βHSD2 siRNA individually in transformed RT101 cells, and the inhibition of 11βHSD2
by each siRNA resulted in significantly decreased colony formation as seen in the colony quantification of the last panel. P < 0.05 were
considered statistically significant (*). Densitometry shown at right of all Western blots in this figure is the average result of 3 separate
experiments. 11βHSD2 was detected using anti-11βHSD2 antibody
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evaluated, the same trend was observed whereby both tumorigenic
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scramble (Figure 2C). Further, we found that transient knockdown of

cell lines, MT1/2, and Ca3/7, showed significantly elevated

11βHSD2 in transformed RT101 cells resulted in significantly

11βHSD2 expression when compared to their non-tumorigenic

diminished colony formation over a 10-day period when compared

counterpart, 3PC cells (Figure 2A). In both models, we report for the

to the non-specific scramble (Figure 2C). Using a pool of siRNAs for

first time in skin, that upregulation of 11βHSD2 occurs in

11βHSD2 and 3 distinctly individual siRNA for 11βHSD2, we observed

transformed cells as compared to normal skin cells. To validate

similar results, whereby transient knockdown of 11βHSD2 resulted in

these findings in a human in vitro model, we further characterized

significantly reduced RT101 colony formation in soft agar with both

11βHSD2 basal expression in normal HaCaT human skin cells and

the pooled siRNA and also with 2 individual siRNA specific for

compared it to highly dysplastic human skin cells (PM1) and

11βHSD2 (Figure 2C).

metastatic skin cancer cells (Met4). Our results show a considerable
increase in 11βHSD2 expression in PM1 highly dysplastic human
skin cells and Met4 skin cancer cells when compared to HaCaT
normal human skin cells (Figure 2B). These results parallel those
which we obtained in our mouse in vitro studies and align with
similar findings in other cancer types in the literature.

2.3 | DMBA/TPA successfully induced development
of papilloma and squamous cell carcinoma, which
could both be greatly inhibited by GA treatment
To determine the chemopreventive effect of GA, we performed
DMBA-initiated and TPA-promoted mouse skin carcinogenesis in

2.2 | 11βHSD2 transient knockdown in soft agar
significantly reduces TPA-induced colony formation
of JB6 P+ cells and transformed RT101 cells

vivo. Animals from the DMBA/TPA group and the DMBA/TPA/GA
groups were topically administered a single dose of DMBA at
the start of our study, followed by twice weekly doses of
either TPA alone or TPA 30 min after GA treatment for the

As transformed epidermal keratinocytes, RT101 cells will readily form

duration of the study. The representative images of dorsal skin from

colonies in soft agar. Thus, we sought to determine the role of

each respective group seen in Figure 3 demonstrate that DMBA/

11βHSD2 in tumorigenesis by investigating whether 11βHSD2

TPA successfully induced both papilloma during the first phase of

knockdown in a transformed cell line could prevent or diminish colony

our animal study (over 15 weeks) and squamous cell carcinoma

formation in soft agar. As colony formation in the soft agar assay is the

during the second phase of our animal study (26 weeks

most efficacious correlate to tumorigenesis in vitro, determining the

total), respectively. Moreover, representative images show that

effect of 11βHSD2 inhibition utilizing this assay would give great

treatment of animals with DMBA/TPA/GA considerably diminished

insight into future in vivo tumorigenesis studies. When P+ cells were

development of both papilloma and squamous cell carcinomas,

treated with TPA and 11βHSD2 was transiently knocked down, we

with the greatest effect observed in the lowest dose GA group

saw a significant reduction in colony formation as compared to the

(Figures 3A and B).

FIGURE 3 A, Representative images of papillomagenesis in the indicated groups after 15 weeks of treatment. When compared to vehicletreated animals (top panel), GA treatment resulted in significant inhibition of tumorigenesis as can be seen in representative images of all
three DMBA/TPA/GA groups (bottom panel). B, Representative images of development of papilloma and squamous cell carcinoma in the
indicated groups after 26 weeks of treatment. When compared to vehicle-treated animals (top panel), GA treatment resulted in significant
inhibition of tumorigenesis as can be seen in representative images of all three DMBA/TPA/GA groups (bottom panel)

108
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2.6 | GA significantly inhibits TPA-induced 11βHSD2
expression in long-term mouse tumor tissue
As the animal data shows a significant effect of GA-mediated
11βHSD2 inhibition on tumorigenesis in the DMBA/TPA model of
skin carcinogenesis, our next question was whether inhibition of

Our study, involving the treatment of FVB mice with GA over the

11βHSD2 by GA played a part in the results we observed. Therefore,

length of 26 weeks provides considerable support of a chemopreven-

we performed Western blot analyses on tumor tissues isolated from

tive role for this compound in DMBA/TPA-induced skin carcinogene-

mice at both short-term and long-term endpoints to characterize

sis. Firstly, GA-mediated 11βHSD2 inhibition significantly reduced

11βHSD1 and 11βHSD2 in both phases of the study. Our results

average tumor weight in grams when compared to the TPA control

showed that in both the short- and long-term phases of the study,

group (Figure 4A). Compared to the DMBA/TPA-treated group, GA

11βHSD2 protein expression was significantly induced by treatment

significantly reduced the tumor incidence (Figure 4B) and multiplicity

with TPA when compared to vehicle-treated animals (Figure 5). This

of skin tumor formation (Figure 4C). Tumor incidence data over both

suggests a possible novel role for 11βHSD2 in the multifactorial

phase I and phase II of our in vivo study (26 weeks) show significant

process of carcinogenesis as many other studies have reported similar

decreases in tumor incidence in TPA/GA(L) and TPA/GA(H) group for

findings in other types of cancer. Moreover, an overall trend amongst

weeks 6-16 when compared to TPA control. Although TPA/GA(L) did

the 11βHSDs in both short- and long-term phases was observed,

not reach significance, this dose was still able to reduce tumor

wherein 11βHSD1 was higher in vehicle-treated tissue than in TPA-

incidence when compared to the TPA alone group. Here, tumor

treated tissue, and conversely 11βHSD2 was higher in TPA-treated

incidence is defined as the number of animals presenting with at least

tissues and lower in vehicle-treated tissues (Figure 5). These results

one tumor. Moreover, it substantially delayed the tumor latency period

suggest 11βHSD2 may play a role in tumorigenesis in NMSC, as a

by 2 weeks in the lowest GA dose (Figure 4D). Treatment with GA in all

switch in 11βHSD1/11βHSD2 expression like the one we observed in

three experimental groups (low, medium, and high [GA]) resulted in an

our Western blot analyses has been shown in other cancer models.

increase in percent tumor-free mice, with TPA/GA(L) and TPA/GA(H)

Additionally, both short- and long-term studies showed a considerable

showing significant increases when compared to TPA control.

reduction in TPA-induced 11βHSD2 protein expression in the TPA/GA

Even as late as 16 weeks, there is approximately a 40% difference

(L) group when compared to the TPA control (Figure 5), with the effect

in tumor-free mice in the TPA/GA(L) group when compared to the

in the short-term being the most dramatic. Taken together, these

TPA control group which dropped below 50% tumor-free mice by

findings may suggest an important role for 11βHSD2 in NMSC, where

10 weeks.

it may be significantly induced by TPA-treatment to aid in NMSC
development or progression.

2.5 | GA significantly decreases squamous cell
carcinoma incidence when compared to DMBA/TPA
alone, but does not have the same effect on
papilloma incidence

3 | DISCUSSION
As GCs are known to play an essential role as regulators of cell
proliferation and differentiation, modulating their activation in a

While GA treatment resulted in significant reduction of tumor

tissue-specific manner could be extremely advantageous in terms of

incidence and an increase in tumor latency, it was also important to

inhibiting the induction of certain cancers. 11βHSDs are key

qualify whether this treatment specifically targeted the development

regulators of GC activation/inactivation whose function happens

of a particular type of lesion. Therefore, H&E stained tissues were

at the pre-receptor level, and therefore these enzymes could serve

analyzed by a pathologist to determine the specific lesion incidence in

as potential therapeutic targets in for skin cancer. Recently, several

each group. As malignant conversion from papilloma to SCC is a critical

studies have reported aberrant 11βHSD2 expression in cancer cells

step in the later stage of the DMBA/TPA two-stage carcinogenesis

versus normal cell counterparts, suggested a role for 11βHSD2 in

method, results from this analysis offer further insight into the specific

transformation, and the possibility that inhibition of this GC-

effect of GA on tumorigenesis. Our results show that GA-mediated

modulating enzyme could serve as a novel therapeutic target.13

11βHSD2 inhibition significantly decreased percent SCC incidence in

For example, lung cancer studies have revealed that 11βHSD2

the DMBA/TPA/GA(L) and DMBA/TPA/GA(H) groups by approxi-

expression was increased in human lung cancers and experimental

mately 40% (Figure 4E). Although there was a decrease in papilloma

lung tumors.22 When 11βHSD2 was inhibited, lung tumor growth

incidence in the DMBA/TPA/GA(L) group as well, it did not reach

and invasion were suppressed and this correlated with increased

significance. As significant differences between papilloma incidences

active glucocorticoid levels in tissues.22 Other noteworthy findings

across all groups were undetectable, but two groups showed a

occurred in colon cancer, wherein 11βHSD2 inhibition by both

significant reduction in SCC as compared to DMBA/TPA control, it is

pharmacological inhibitor and gene silencing prevented adenoma

possible that GA may have a stronger negative effect on conversion

formation, tumor growth, and metastasis in an animal model.17

from papilloma to SCC rather than papillomagenesis.

Relevant findings have also been elucidated in breast cancer as well,
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FIGURE 4 A, Chemopreventive effect of GA on DMBA/TPA-induced skin cancer in FVB mice. GA treatment significantly reduces average
tumor weight in the short-term timeline when compared to DMBA/TPA control. Twice-weekly topical application of GA 30 min prior to TPAtreatment resulted in a significant decrease in average tumor weight in all three experimental DMBA/TPA/GA groups (low, medium, and high
doses). B, Tumor incidence data over both phase I and phase II of our in vivo study (26 weeks) show significant decreases in tumor incidence
in TPA/GA(L) and TPA/GA(H) group for weeks 6-16 when compared to TPA control. C, Average number of tumors per mouse over both
phase I and phase II of our in vivo study (26 weeks). All 3 groups elicited a significant reduction in average number of tumors/mouse when
compared to the TPA alone group. D, Latency of tumors was increased in all experimental groups compared to TPA control by 2 weeks.
Treatment with GA in all three experimental groups (low, medium, and high [GA]) resulted in an increase in percent tumor-free mice, with
TPA/GA(L) and TPA/GA(H) showing significant increases when compared to TPA control. E, Incidence of SCC is significantly decreased by GA
treatment; Histological analysis of tissue samples after undergoing 26 weeks of TPA-treatments reveals that treatment with GA significantly
decreased the percent incidence of SCC in two out of three experimental groups (TPA/GA(L) and TPA/GA(H)). P < 0.05 were considered to be
statistically significant (*)

where 11βHSD2 was observed in 66% of the breast tumor samples
evaluated.

12

Overexpression of 11βHSD2 in MCF-7 cells reversed

In these studies, we characterized 11βHSD2 in well-established in
vitro and in vivo models of NMSC, which had never been previously

the antiproliferative effects of GCs in these cells and increased

evaluated. We also sought to determine if 11βHSD2 plays a role in the

overall cell growth.23 These results suggest an increased expression

multifactorial process of NMSC transformation. We hypothesized that

of 11βHSD2 may have the ability to abrogate the antiproliferative

11βHSD2 contributes to malignant transformation in NMSC. We

action of GCs in certain tissues.

observed greater expression of 11βHSD2 in transformed RT101 cells
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FIGURE 5 11βHSD2 expression is significantly induced upon TPA treatment, and GA abrogates this increase in expression; (A)
Representative Western blots from both short-term and long-term endpoints of our DMBA/TPA two stage carcinogenesis study and (B)
Quantitative analysis of densitometry showing relative 11βHSD1 and 11βHSD2 expression normalized to β-actin. P < 0.05 were considered to
be statistically significant (*)
when compared to their normal counterparts, which correlates with

types of mouse NMSC cells, and found 11βHSD2 was upregulated in

the “switch” observed in the literature in other types of cancer

both tumorigenic cell lines, MT1/2 and Ca3/7, but not in the non-

whereby normal cells will begin to preferentially express 11βHSD2 as

tumorigenic line, 3PC. These results suggest 11βHSD2 may play a role

they undergo transformation. When JB6+ epidermal keratinocytes

in transformation of NMSC, and may serve as a novel target for

underwent transformation by the addition of tumor promoter, TPA, we

prevention. We then validated this elevated 11βHSD2 expression

observed a significant increase in 11βHSD2 expression. Further, we

trend in a human in vitro skin cancer model and found that the same

tested a second well-established in vitro mouse model of NMSC to

upregulation of 11βHSD2 evident in our mouse models was also

determine if the upregulation of 11βHSD2 was prevalent in different

present in human cells. After using mouse and human cell lines to show
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conversely 11βHSD2 was higher in TPA-treated tissues and lower in

normal counterparts, we then wanted to investigate this critical

vehicle-treated tissues. These results correlate with the “switch”

enzyme's role in transformation.

reported in the literature in other models which we mentioned earlier

To determine whether 11βHSD2 played a critical role in

in the introduction. These findings further validate our earlier in vitro

transformation of mouse epidermal keratinocytes, we used both

studies, where we observed a significant induction of 11βHSD2

pooled siRNA and individual siRNA to transiently knockdown

protein expression upon TPA treatment, and saw the same inverse

11βHSD2 in transformed RT101 cells. We used the anchorage

expression trend between 11βHSD1 and 11βHSD2. Finally, GA

independent colony formation assay to determine what effect an

abrogated TPA-induced 11βHSD2 protein expression in both short-

11βHSD2 knockdown would have on transformed RT101's ability to

and long-term phases. Because GA-mediated 11βHSD2 inhibition

grow in soft agar. Our results showed that both pooled siRNA and two

resulted in significantly reduced tumor incidence as well as a delay of

of the individual siRNA were all capable of producing a knockdown

tumor onset in our in vivo work, this may elucidate a possible

which significantly reduced RT101 colony formation in soft agar over

therapeutic approach for NMSC by modulating the 11βHSD2 enzyme

the course of 10 days. When we performed a transient 11βHSD2

in a tissue-specific manner. If GA is used to locally inhibit 11βHSD2

knockdown in TPA-treated JB6 P+ cells, we saw a significant decrease

rather than systemic inhibition, adverse effects caused by 11βHSD2

in colony formation when compared to the scramble TPA-treated P+

inhibition should not be expected.

cells. Our in vitro results suggest 11βHSD2 may serve as a novel and

Given the rise of NMSC incidence, high rate of lesion recurrence,

critical target for inhibition of NMSC development. These data showed

and serious tissue damage that can occur from lesion development,

for the first time in detail, increased 11βHSD2 expression in two well-

elucidating novel chemopreventive approaches to NMSC and a greater

established mouse models of NMSC and also a well-established human

understanding of the mechanisms by which they occur are of critical

model of NMSC; these findings provide substantial support of a

importance.2,25–27 The goal of this study, was to investigate whether

possible role for this GC-regulating enzyme in transformation in a

11βHSDs, pre-receptor regulators of GC activation, played a role in

cancer where it had previously not been evaluated. As the anchorage

NMSC development and/or progression; this was achieved by using

independent colony formation assay is typically considered to be an in

pharmacological 11βHSD2 inhibitor, GA, in conjunction with tumor

vitro indicator of tumorigenicity, these results suggest that when

promoter, TPA, to determine if 11βHSD2 inhibition could significantly

11βHSD2 is inhibited in an animal model, we may be able to achieve

abrogate tumorigenesis. Major findings of this study are that 11βHSD2

minimized tumor size or diminished tumor formation. Therefore, we

expression is upregulated in TPA-treated in vitro and in vivo models of

next sought to test this hypothesis in an in vivo mouse NMSC model.

NMSC, and both genetic knockdown and pharmacological inhibition of

We evaluated the effect of 11βHSD2 expression inhibition in a

11βHSD2 result in significantly reduced soft agar colony formation

well-established in vivo model of NMSC using phytonutrient, GA as an

and tumorigenesis in cell and animal models respectively. Results of

inhibitor of the enzyme. We chose GA because phytonutrients are

this study are significant because the specific role of 11βHSDs in

naturally derived compounds isolated from plants, which can modulate

NMSC have not been well-studied, and many others have suggested

disease progression and have been widely studied for their efficacious

11βHSD2 may be a pro-proliferative force because of its ability to

use in cancer and other diseases.24 Pentacyclic triterpenoids have

inactivate glucocorticoids in a tissue-specific manner.12–14,23 The role

been shown to be efficacious in inhibition of skin tumorigenesis,

of 11βHSD2 in tumorigenesis has already been elucidated in colorectal

however, the role of 11βHSD2 as a target in this chemopreventive

cancer, and its inhibition has suppressed colon carcinogenesis in both

process has not been evaluated. In our in vivo studies, we observed a

mouse and human models.17,28 As GCs are well-known inhibitors

significant decrease in tumor incidence, a significant decrease in

of cell proliferation and inducers of cell differentiation via GRs, pre-

squamous cell carcinoma incidence, and an increase in tumor latency in

receptor regulation of the availability of active GCs to the receptor is

the DMBA/TPA/GA experimental groups as compared to the DMBA/

vital for tightly maintaining the proper function of GCs in specific

TPA group. Histopathological evaluation of tissues showed that topical

situations. It is highly disadvantageous for the tumor environment to

administration of GA did not have any adverse effects on the epidermis

have the capability to increase 11βHSD2 expression in a tissue-

or mouse weight over 26 weeks. Histological analysis of the DMBA/

specific manner to achieve a decrease in the functionality of GCs; such

TPA group also show a characteristically thickened epidermis, that is,

an environment would result in GC inactivation, reduced anti-

absent in GA control groups and diminished in DMBA/TPA/GA

inflammatory signals, and a setting that favors tumorigenesis. Further

experimental groups. To investigate whether inhibition of 11βHSD2

investigation into understanding the mechanistic players involved in

played a role in the decrease in tumors exerted by GA treatment, we

GA-mediated 11βHSD2 inhibition is certainly warranted to provide a

evaluated 11βHSD2 protein expression in tissues from both phase 1

more thorough understanding of the impact of these findings. In

(short-term) and phase 2 (long-term) animals. Our results show a

conclusion, this work has characterized the 11βHSD enzymes in well-

significant induction of 11βHSD2 protein expression in in TPA-treated

established human and mouse in vitro and mouse in vivo models of skin

tissues when compared to vehicle-treated tissues from both short- and

cancer, shown a significant role for 11βHSD2 in transformation of

long-term phases. An overall trend amongst the 11βHSDs in both

NMSC in mouse in vitro models, and elucidated GA-mediated

short- and long-term phases was observed, wherein 11βHSD1 was

11βHSD2 inhibition to be a potential chemopreventive target for

higher in vehicle-treated tissue than in TPA-treated tissue, and

prevention tumorigenesis in a well-studied mouse model of NMSC.
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